Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Forbion Capital Partners
About
Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
- 11 - 50
Highlights
Details
- Industries
- Biotechnology,Health Care,Venture Capital
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Investor Type
- Venture Capital
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Nov 22, 2022
CatalYm
|
Series C | €50M | Biotechnology | — |
|
Mar 17, 2021
Amphista Therapeutics
|
Series B | $53M | Biopharma | Yes |
|
Nov 19, 2020
CatalYm
|
Series B | €50M | Biotechnology | — |
|
Sep 8, 2017
Replimune Group
|
Series B | $55M | Biotechnology | — |
|
Aug 5, 2016
CatalYm
|
Seed | — | Biotechnology | — |
